Vetter Announces Plan to Build Manufacturing Site in Germany with €1.5 Billion CDMO Investment
Published: 02 Apr 2026
Author: Precedence Research
Vetter is one of the world's leading pharmaceutical service providers for the production of injectable drugs. Announcement of Vetter's plan to build a state-of-the-art production facility in the Saarland region of southwest Germany, this make significant step for the company’s long-term global growth strategy. Construction is scheduled in the second quarter of 2026, and €480 million has been allocated for the first construction phase.
This location was chosen following careful strategic investment, and Contract Development and Manufacturing Organisation (CDMO) acquired the approximately 95-acre industrial property in the city of Saarlouis. Vetter sees the potential to create up to 2,000 jobs in the long term.
Market growth is driven by the Pharmaceutical service provider.
According to Towards Healthcare, the Sterile injectables CDMO market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 42.1 billion in 2026 to approximately USD 109.82 billion by 2035, representing a compound annual growth rate (CAGR) of 11.24% from 2026 to 2035. Growth is driven by increasing demand for injectable drugs, increasing outsourcing of manufacturing to CDMOs, and the development of complex biologics and gene therapies.
Expansion in Europe impacts the commercial supply chain.
As construction is scheduled for the second quarter of 2026, the CDMO has submitted the building permit application for a multi-phase facility that is expected to create up to 2,000 jobs over the long term.
Chairman of the advisory board Senator h.c. Udo J. Vetter, in a press release stating the construction of our new production facility in Germany, we continue on our path to sustainable growth. Long-term success will strike the right balance between stability and expansion.
About Vetter
Vetter is a leading Contract Development and Manufacturing Organisation (CDMO) with headquarters in Ravensburg, Germany. It is a global player as a pharmaceutical service provider in the Asia-Pacific markets of Japan, China, South Korea, and Singapore, with sales locations. It is committed to quality, innovation, and responsibility in the production of sterile pharmaceuticals, improving the lives of patients worldwide.
To meet growing customer demand and increasing market requirements, the company is investing in its existing sites in Germany, Austria, and the United States.
A recent report by Towards Healthcare highlights that the Sterile injectables CDMO Market growth is witnessed with emerging technologies, and competitive movements shaping the sterile injectables CDMO market, offering comparable quality, safety, and efficacy.